Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study

被引：28

作者：

Wang, Hua ^{[1
,2
,7
]}

Wuxiao, Zhi-Jun ^{[4
]}

Zhu, Jiayu ^{[5
]}

Wang, Zhihui ^{[6
]}

Wang, Ke-Feng ^{[1
,2
]}

Li, Su ^{[1
,3
]}

Chen, Xiaoqin ^{[1
,2
]}

Lu, Yue ^{[1
,2
,7
]}

Xia, Zhong-Jun ^{[1
,2
,7
]}

机构：

[1] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China

[2] Sun Yat Sen Univ, Ctr Canc, Dept Hematol Oncol, Guangzhou 510060, Guangdong, Peoples R China

[3] Sun Yat Sen Univ, Ctr Canc, Clin Trial Ctr, Guangzhou 510060, Guangdong, Peoples R China

[4] Hai Nan Med Coll, Affiliated Hosp, Dept Hematol & Oncol, Haikou, Hainan, Peoples R China

[5] Southern Med Univ, Nan Fang Hosp, Dept Obstet & Gynecol, Guangzhou, Guangdong, Peoples R China

[6] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Med Oncol, Zhuhai, Guangdong, Peoples R China

[7] Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China

来源：

LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 04期

基金：

中国国家自然科学基金;

关键词：

Extranodal NK/T-cell lymphoma; induction chemotherapy; EPOCH; GELOX; response; survival; UPPER AERODIGESTIVE TRACT; INVOLVED-FIELD RADIATION; NON-HODGKINS-LYMPHOMA; PERIPHERAL T-CELL; NASAL-TYPE; PROGNOSTIC-FACTORS; P-GLYCOPROTEIN; PHASE-II; REGIMEN; EXPRESSION;

D O I：

10.3109/10428194.2014.939964

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Optimal chemotherapy regimen for Extranodal natural killer/T-cell lymphoma (ENKTL) has not yet been defined. We retrospectively compared the outcome of 93 patients newly diagnosed with stage IE to IIE ENKTL who received gemcitabine, oxaliplatin and L-asparaginase (GELOX) (n = 40) or etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone (EPOCH) (n = 53) as induction chemotherapy. After induction chemotherapy, the complete response (CR) rate and overall response rate (ORR) for the GELOX group were higher than those for the EPOCH group (70.0% vs. 41.5%, p = 0.007 for CR; 87.5% vs. 67.9%, p = 0.047 for ORR). The GELOX regimen resulted in significantly superior 5-year progression-free survival (PFS) (79.0% vs. 46.5%, p = 0.005) and overall survival (OS) rates (78.9% vs. 50.4%, p = 0.003). Toxicity of both regimens was acceptable. The GELOX regimen produces a better long outcome with less toxicity than the EPOCH regimen for patients with early stage ENKTL.

引用

页码：971 / 977

页数：7

共 36 条

[1] Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project [J].